To determine the effects of STAT3 and EGFR inhibition on osteosarcoma cell proliferation and migration, MG63 and U2OS cells were incubated with the STAT3 inhibitor LY5 (1μM) or the EGFR inhibitor erlotinib (1μM). Here, STAT3 is linked to osteosarcoma.